A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
'Left-Handed Girl' named one of top 5 international films by NBR
12/05/2025 12:52 PM - Business
U.S. dollar higher in Taipei trading
12/05/2025 10:11 AM - Society
Taiwan headline news
12/05/2025 10:08 AM - Business
Taiwan shares open little changed
12/05/2025 09:21 AM - Business
Taiwan chip sector urged to reduce reliance on China's rare earths
12/04/2025 10:25 PM